🎉 M&A multiples are live!
Check it out!

Co-Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Co-Diagnostics and similar public comparables like Myomo, Perspective Therapeutics, and InfuSystem.

Co-Diagnostics Overview

About Co-Diagnostics

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.


Founded

2013

HQ

United States of America
Employees

155

Financials

LTM Revenue $3.6M

LTM EBITDA n/a

EV

-$19.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Co-Diagnostics Financials

Co-Diagnostics has a last 12-month revenue of $3.6M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Co-Diagnostics achieved revenue of $6.8M and an EBITDA of -$41.5M.

Co-Diagnostics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Co-Diagnostics valuation multiples based on analyst estimates

Co-Diagnostics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.8M $4.1M XXX XXX XXX
Gross Profit $86.3M $28.7M XXX XXX XXX
Gross Margin 1267% 694% XXX XXX XXX
EBITDA -$41.5M n/a XXX XXX XXX
EBITDA Margin -609% NaN% XXX XXX XXX
Net Profit $36.7M -$14.2M XXX XXX XXX
Net Margin 538% -344% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Co-Diagnostics Stock Performance

As of March 17, 2025, Co-Diagnostics's stock price is $0.

Co-Diagnostics has current market cap of $15.5M, and EV of -$19.8M.

See Co-Diagnostics trading valuation data

Co-Diagnostics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$19.8M $15.5M XXX XXX XXX XXX $-1.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Co-Diagnostics Valuation Multiples

As of March 17, 2025, Co-Diagnostics has market cap of $15.5M and EV of -$19.8M.

Co-Diagnostics's trades at -5.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Co-Diagnostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Co-Diagnostics and 10K+ public comps

Co-Diagnostics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$19.8M XXX XXX XXX
EV/Revenue -4.8x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Co-Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Co-Diagnostics Valuation Multiples

Co-Diagnostics's NTM/LTM revenue growth is -58%

Co-Diagnostics's revenue per employee for the last fiscal year averaged $44K, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Co-Diagnostics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Co-Diagnostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Co-Diagnostics and other 10K+ public comps

Co-Diagnostics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -39% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $44K XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue 101% XXX XXX XXX XXX
G&A Expenses to Revenue 210% XXX XXX XXX XXX
R&D Expenses to Revenue 337% XXX XXX XXX XXX
Opex to Revenue 665% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Co-Diagnostics Public Comps

See public comps and valuation multiples for Medical Devices and Laboratory Services comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
SmartVest XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
Myomo XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Co-Diagnostics M&A and Investment Activity

Co-Diagnostics acquired  XXX companies to date.

Last acquisition by Co-Diagnostics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Co-Diagnostics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Co-Diagnostics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Co-Diagnostics

When was Co-Diagnostics founded? Co-Diagnostics was founded in 2013.
Where is Co-Diagnostics headquartered? Co-Diagnostics is headquartered in United States of America.
How many employees does Co-Diagnostics have? As of today, Co-Diagnostics has 155 employees.
Who is the CEO of Co-Diagnostics? Co-Diagnostics's CEO is Mr. Dwight H Egan.
Is Co-Diagnostics publicy listed? Yes, Co-Diagnostics is a public company listed on NAS.
What is the stock symbol of Co-Diagnostics? Co-Diagnostics trades under CODX ticker.
When did Co-Diagnostics go public? Co-Diagnostics went public in 2017.
Who are competitors of Co-Diagnostics? Similar companies to Co-Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem.
What is the current market cap of Co-Diagnostics? Co-Diagnostics's current market cap is $15.5M
What is the current revenue of Co-Diagnostics? Co-Diagnostics's last 12-month revenue is $3.6M.
What is the current EV/Revenue multiple of Co-Diagnostics? Current revenue multiple of Co-Diagnostics is -5.5x.
What is the current revenue growth of Co-Diagnostics? Co-Diagnostics revenue growth between 2023 and 2024 was -39%.
Is Co-Diagnostics profitable? Yes, Co-Diagnostics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.